Business Context and Reporting Period
Company: BioLife Solutions, Inc. (BLFS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: BioLife develops and markets patented hypothermic storage and cryopreservation solutions (HypoThermosol and CryoStor) for cells, tissues, and organs. The company serves academic, clinical, and commercial research markets. In 2008, the company transitioned from outsourcing manufacturing to a contract manufacturer (Bioserv) to internal manufacturing to reduce costs, with the new facility expected to be operational in Q2 2009.
Key Financial Metrics
| Metric | 2008 | 2007 |
|---|---|---|
| Total Revenue | $1,322,497 | $972,262 |
| Product Sales | $1,277,497 | $945,595 |
| Licensing Revenue | $45,000 | $26,667 |
| Gross Profit | $551,851 | $509,156 |
| Gross Margin | 41.7% | 52.4% |
| Net Loss | $(2,775,117) | $(2,851,774) |
| Accumulated Deficit | $(47,442,870) | $(44,667,753) |
| Cash and Equivalents | $98,724 | $56,497 |
| Working Capital | $113,378 | $123,770 |
| Total Debt (Related Parties) | $5,063,127 | $2,750,000 |
| Net Cash Used in Operating Activities | $(2,113,418) | $(2,708,979) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 36% to $1.32 million, driven by a 35% increase in product sales due to new customers in cell therapy and cord blood banking markets.
- Margin Compression: Gross margin declined from 52.4% to 41.7%. This was primarily due to higher production costs associated with the Contract Manufacturing Organization (CMO) compared to prior internal manufacturing periods.
- Expense Reduction: Sales and marketing expenses decreased 47% to $372,324 due to reduced headcount and lower travel/commission costs. However, General and Administrative (G&A) expenses increased slightly (1%) to $1.93 million, driven by higher legal fees related to ongoing litigation.
- Debt Increase: Long-term debt related to shareholders increased significantly from $2.75 million to $5.06 million. This reflects the refinancing of prior notes and new draws under a Secured Convertible Multi-Draw Term Loan Facility.
- Inventory Build-up: Inventory increased from $99,062 to $625,291, reflecting the transition to internal manufacturing and stockpiling of raw materials and finished goods.
Outlook, Risks, and Contingencies
- Liquidity and Going Concern: The company has an accumulated deficit of $47.4 million and incurred a net loss of $2.78 million in 2008. The auditors have raised substantial doubt about the company's ability to continue as a going concern. Operations are dependent on continued access to a $9 million credit facility provided by two related-party investors (Thomas Girschweiler and Walter Villiger).
- Manufacturing Transition: The company is transitioning to in-house manufacturing to lower costs. The facility is expected to be validated and operational in Q2 2009. Delays in validation could impact the ability to meet customer demand.
- Legal Proceedings: The company is involved in multiple lawsuits:
- Suits filed by former CEO John G. Baust and former employee Kristi Snyder alleging breach of employment agreements and seeking damages up to $300,000 each.
- A lawsuit filed by the company against Cell Preservation Services, Inc. (CPSI) and Coraegis Bioinnovations, Inc. (controlled by the Baust family) alleging misappropriation of trade secrets and breach of contract.
- Discrimination complaints filed by the Bausts with the NY Division of Human Rights, which were dismissed but are currently under appeal.
- Regulatory Risks: While current products are not subject to specific FDA pre-market approval as excipients, future expansion into embryo/gamete preservation or organ transplants would require FDA approval, which is costly and time-consuming.
Investor Verification Checklist
- Debt Covenants and Conversion: Verify the terms of the $9 million Multi-Draw Term Loan Facility, specifically the conversion triggers (85% discount on equity financing) and the risk of dilution to existing shareholders.
- Manufacturing Validation: Confirm the timeline for the validation of the new internal manufacturing facility and the impact of any delays on cost of goods sold and revenue recognition.
- Legal Exposure: Assess the potential financial impact of the ongoing litigation with the Baust family and former employees, including potential damages and legal fees.
- Customer Concentration: Review the dependency on top customers, as two customers accounted for approximately 36% of gross accounts receivable and significant revenue portions in 2008.
- Cash Burn Rate: Monitor the company's cash burn rate against the remaining availability under the credit facility ($2.5 million remaining as of Jan 2009) to determine the runway for operations.